Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) The approval by the National Medical Products Administration (NMPA) in China was based on results from the Phase III PREVENT trial.1 In the trial, Soliris met the primary…